Abstract
The preparation of several N-aryl-substituted (phenyl, p-methylphenyl, p-methoxyphenyl, p-nitrophenyl, p-aminophenyl, p-hydroxyphenyl) 3-hydroxy-2-methylpyridin-4-ones as well as their adamantyl derivatives is described, and their in vitro antitumor properties were investigated. The compounds were synthesized in good yields using efficient synthetic routes and methods. Prepared derivatives were evaluated in an antiproliferative in vitro study on 4 cancer cell lines, namely HCT 116 (colon carcinoma), H 460 (lung carcinoma), MCF-7 (breast carcinoma) and K562 (chronic myelogenous leukemia). All tested compounds showed antiproliferative activity ranging from moderate to strong on all inspected cell lines with 4 adamantane containing derivatives being active and selective at low micromolar IC\(_{50}\) concentrations on HCT 116, H 460 and MCF-7. LDH cytotoxicity assay revealed that cytotoxic effects occur after 48 h of exposure. It was shown that there was no change in caspase activity in the treated cells, but there were changes in the cell cycle. All treated samples showed reduced number of cells in the S phase with increased G0/G1 (4b, 5a, 5b) and G2/M (4a) phase.
Graphical Abstract
Similar content being viewed by others
References
Santos MA, Chaves S (2015) 3-Hydroxypyridinone derivatives as metal sequestering agents for therapeutic use. Future Med Chem 7:383–410. doi:10.4155/fmc.14.162
Fassihi A, Abedi D, Saghaie L, Sabet R, Fazeli H, Bostaki G, Deilami O, Sadinpour H (2009) Synthesis, antimicrobial evaluation and QSAR study of some 3-hydroxypyridine-4-one and 3-hydroxypyran-4-one derivatives. Eur J Med Chem 44:2145–2157. doi:10.1016/j.ejmech.2008.10.022
Merlot AM, Kalinowski DS, Richardson DR (2013) Novel chelators for cancer treatment: where are we now? Antioxid Redox Sign 18:973–1006. doi:10.1089/ars.2012.4540
Saghaie L, Hider RC (2008) Synthesis and physico-chemical properties of a series of bidentate 3-hydroxypyridin-4-ones iron chelating agents. Res Pharm Sci 3:21–30
Saghaie L, Mirmohammad Sadeghi M, Nikazama A (2006) Synthesis, analysis and determination of partition coefficients of N-arylhydroxypyridinone derivatives as iron chelators. Res Pharm Sci 1:40–48
Ma Y, Zhou T, Kong X, Hider RC (2012) Chelating agents for the treatment of systemic iron overload. Curr Med Chem 19:2816–2827. doi:10.2174/092986712800609724
Santos MA, Gil M, Gano L, Chaves S (2005) Bifunctional 3-hydroxy-4-pyridinone derivatives as potential pharmaceuticals: synthesis, complexation with Fe(III), Al(III) and Ga(III) and in vivo evaluation with \(^{67}\)Ga. J Biol Inorg Chem 10:564–580. doi:10.1007/s00775-005-0003-7
Kalinowski DS, Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharm Rev 57:547–583. doi:10.1124/pr.57.4.2
Zhou T, Ma Y, Kong X, Hider RC (2012) Design of iron chelators with therapeutic application. Dalton Trans 41:6371–6389. doi:10.1039/C2DT12159J
Kovacevic Z, Kalinowski DS, Lovejoy DB, Yu Y, Rahmanto YS, Sharpe PC, Bernhardt PV, Richardson DR (2011) The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem 11:483–499. doi:10.2174/156802611794785190
Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB (2009) Cancer ell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 1790:702–717. doi:10.1016/j.bbagen.2008.04.003
Richardson DR (2002) Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42:267–281. doi:10.1016/S1040-8428(01)00218-9
Becton DL, Bryles P (1988) Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 48:7189–7192
Bierer BE, Nathan DG (1990) The effect of desferrithiocin, an oral iron chelator, on T-cell function. Blood 76:2502–2509
Blatt J, Stitely S (1987) Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res 47:1749–1750
Kaplinsky C, Estrov Z, Freedman MH, Gelfand EW, Cohen A (1987) Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia 1:437–441
Richardson DR, Tran EH, Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295–4306
Donfrancesco A, Deb G, Angioni A, Maurizzio C, Cozza R, Jenkner A, Landolfo A, Boglino C, Helson L (1993) D-CECaT: a breakthrough for patients with neuroblastoma. Anti-Cancer Drugs 4:317–321
Barman Balfour JA, Foster RH (1999) Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs 58:553–578
Sheppard LN, Kontoghiorghes GJ (1993) Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals. Arzneimittelforschung 43:659–663
Dehkordi LS, Liu ZD, Hider RC (2008) Basic 3-hydroxypyridin-4-ones: potential antimalarial agents. Eur J Med Chem 43:1035–1047. doi:10.1016/j.ejmech.2007.07.011
Rai BL, Liu ZD, Liu DY, Lu SL, Hider RC (1999) Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: design of orally active chelators with clinical potential. Eur J Med Chem 34:475–485. doi:10.1016/S0223-5234(99)80097-X
Schlindwein W, Waltham E, Burgess J, Binsted N, Nunes A, Leite A, Rangel M (2006) New lipophilic 3-hydroxy-4-pyridinonate iron(III) complexes: synthesis and EXAFS structural characterisation. Dalton Trans 1313–1321: doi:10.1039/b509671e
Liu J, Obando D, Liao V, Lifa T, Codd R (2011) The many faces of the adamantyl group in drug design. Eur J Med Chem 46:1949–1963. doi:10.1016/j.ejmech.2011.01.047
Spasov AA, Khamidova TV, Bugaeva LI, Morozov IS (2000) Molecular-biological problems of drug design and mechanism of drug action. Adamantane derivatives: pharmacological and toxicological properties. Pharm Chem J 34:1–7. doi:10.1007/BF02524549
Maugh TH (1976) Amantadine: an alternative for prevention of influenza. Science 192:130–131. doi:10.1126/science.192.4235.130
Liddell JR, Obando D, Liu J, Ganio G, Volitakis I, Mok SS, Crouch PJ, White AR, Codd R (2013) Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Free Radic Biol Med 60:147–156. doi:10.1016/j.freeradbiomed.2013.01.027
Wanka L, Iqbal K, Schreiner PR (2013) The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev 113:3516–3604. doi:10.1021/cr100264t
Tetko IV, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, Palyulin VA, Radchenko EV, Zefirov NS, Makarenko AS, Tanchuk VY, Prokopenko VV (2005) Virtual computational chemistry laboratory—design and description. J. Comput-Aided Mol Des 19:453–463. doi:10.1007/s10822-005-8694-y
Lam K, Timmerman H (2012) Lipid-based formulations for oral delivery of lipophilic drugs. Drug Discov Today Technol 9:e97–e104. doi:10.1016/j.ddtec.2012.03.002
Ribić R, Habjanec L, Vranešić B, Frkanec R, Tomić S (2012) Synthesis and immunostimulating properties of novel adamant-1-yl tripeptides. Chem Biodivers 9:777–788. doi:10.1002/cbdv.201100232
Ribić R, Habjanec L, Frkanec R, Vranešić B, Tomić S (2012) Influence of mannosylation on immunostimulating activity of adamant-1-yl tripeptide. Chem Biodivers 9:1373–1381. doi:10.1002/cbdv.201200008
Štimac A, Šegota S, Dutour Sikirić M, Ribić R, Frkanec L, Svetličić V, Tomić S, Vranešić B, Frkanec R (2012) Surface modified liposomes by mannosylated conjugates anchored via the adamantyl moiety in the lipid bilayer. Biochim Biophys Acta Biomembr 1818:2252–2259. doi:10.1016/j.bbamem.2012.04.002
Ribić R, Habjanec L, Vranešić B, Frkanec R, Tomić S (2011) Synthesis and biological evaluation of new mannose derived immunomodulating adamantyltripeptides. Croat Chem Acta 84:233–244. doi:10.5562/cca1827
Ribić R, Kovačević M, Petrović Peroković V, Gruić-Sovulj I, Rapić V, Tomić S (2010) Synthesis and biological activity of mannose conjugates with 1-adamantamine and ferrocene amines. Croat Chem Acta 83:421–431
Car Ž, Hrenar T, Petrović Peroković V, Ribić R, Seničar M, Tomić S (2014) Mannosylated \(N\)-aryl substituted 3-hydroxypyridine-4-ones: synthesis, hemagglutination inhibitory properties and molecular modeling. Chem Biol Drug Des 84:393–401. doi:10.1111/cbdd.12329
Petrović Peroković V, Prugovečki B, Car Ž (2013) Synthesis, crystal and molecular structure of novel adamantyl derivatives of \(n\)-aryl substituted 3-hydroxy-2-methylpyridine-4-ones. Croat Chem Acta 86:317–323. doi:10.5562/cca2339
Gojmerac Ivšić A, Tomišić V, Car Ž, Prugovečki B, Tomić S (2011) Synthesis and characterization of a new 4-pyridone derivative and its complexation of iron(III). J Mol Struct 990:237–243. doi:10.1016/j.molstruc.2011.01.051
Petrović Peroković V, Gojmerac Ivšić A, Car Ž, Tomić S (2014) Synthesis of 3-hydroxy-1-(\(p\)-methoxyphenyl)-2-methylpyridine-4-one and spectrophotometric extraction studies on its complexation of vanadium(V). Croat Chem Acta 87:103–109. doi:10.5562/cca2366
Jakopčić K, Tamhina B, Zorko F, Herak MJ (1977) Synthesis and physical properties of some new 4-pyridone extractants. J Inorg Nucl Chem 39:1201–1203. doi:10.1016/0022-1902(77)80345-X
Zhang Z, Rettig SJ, Orvig C (1992) Physical and structural studies of \(N\)-carboxymethyl- and \(N\)-(\(p\)-methoxyphenyl)-3-hydroxy-2-methyl-4-pyridinone. Can J Chem 70:763–770
Färber M, Osiander H, Severin T (1994) Synthesis of N-substituted 3-hydroxy-2-methyl-4-pyridones and -pyridonimines. J Heterocycl Chem 31:947–956. doi:10.1002/jhet.5570310443
Harris RLN (1976) Potential wool growth inhibitors. Aust J Chem 29:1329–1334. doi:10.1071/CH9761329
Neises B, Steglich W (1978) Simple method for the esterification of carboxylic acids. Angew Chem Int Ed Engl 17:522–524. doi:10.1002/anie.197805221
Gaboriau F, Chantrel-Groussard K, Rakba N, Loyer P, Pasdeloup N, Hider RC, Brissot P, Lescoat G (2004) Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study. Biochem Pharmacol 67:1479–1487. doi:10.1016/j.bcp.2003.12.019
Sadeghi-aliabadi H, Saghaie L, Tadayonnia N, Mirian M (2013) Hydroxypyridinone derivatives: synthesis and cytotoxic evaluation. J Rep Pharm Sci 2:5–15
Saghaie L, Sadeghi-aliabadi H, Kafiri M (2011) Synthesis and biological evaluation of bidentate 3-hydroxypyridin-4-ones iron chelating agents. Res Pharm Sci 6:117–122
Virtual Computational Chemistry Laboratory. http://www.vcclab.org/lab/alogps/. Accessed 20 Feb 2017
Zhang Z, Rettig SJ, Orvig C (1991) Lipophilic coordination compounds: aluminum, gallium, and indium complexes of 1-aryl-3-hydroxy-2-methyl-4-pyridinones. Inorg Chem 30:509–515
Green DE, Ferreira CL, Stick RV, Patrick BO, Adam MJ, Orvig C (2005) Carbohydrate-bearing 3-hydroxy-4-pyridinonato complexes of gallium(III) and indium(III). Bioconjugate Chem 16:1597–1609. doi:10.1021/bc0501808
Mickisch G, Fajta S, Keilhauer G, Schlick E, Tschada R, Alken P (1990) Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT). Urol Res 18:131–136
Supek F, Šumanovac Ramljak T, Marjanović M, Buljubašić M, Kragol G, Ilić N, Šmuc T, Zahradka D, Mlinarić-Majerski K, Kralj M (2011) Could log P be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns. Eur J Med Chem 46:3444–3544. doi:10.1016/j.ejmech.2011.05.009
Mazumder S, Plesca D, Almasan A (2008) In: Mor G, Alvero AB (eds) Apoptosis and cancer: methods and protocols. Humana Press, Totowa, pp 13–21
Cook JA, Mitchell JB (1989) Viability measurements in mammalian cell systems. Anal Biochem 179:1–7. doi:10.1016/0003-2697(89)90191-7
Acknowledgements
The authors wish to thank the Croatian Science Foundation for support of this work (Projects IP-2014-09-7899, IP-2013-11-5660).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Petrović Peroković, V., Car, Ž., Opačak-Bernardi, T. et al. In vitro antiproliferative study of novel adamantyl pyridin-4-ones. Mol Divers 21, 881–891 (2017). https://doi.org/10.1007/s11030-017-9763-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11030-017-9763-6